<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04338438</url>
  </required_header>
  <id_info>
    <org_study_id>BFH-Apatinib&amp;S-1</org_study_id>
    <nct_id>NCT04338438</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Apatinib Mesylate Tablets Combined With Tegio Capsule for First-line Refractory Patients With Late-stage Gastric Cancer</brief_title>
  <official_title>A Study on Efficacy and Safety of Apatinib Mesylate Tablets Combined With Tegio Capsule for First-line Refractory Patients With Late-stage Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, interventional study aimed to observe the efficacy and safety of
      Apatinib Mesylate tablets combined with Tegio capsule for first-line refractory patients with
      late-stage gastric cancer or gastro-esophageal junction cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Actual">February 28, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>3 years</time_frame>
    <description>progression-free survival</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Apatinib Mesylate tablets combined with Tegio capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib Mesylate tablets combined with Tegio capsules</intervention_name>
    <description>Apatinib Mesylate tablets+ Tegio capsules, p.o.</description>
    <arm_group_label>Apatinib Mesylate tablets combined with Tegio capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. age 18-75 yrs;

          -  2. ECOG score 0-2;

          -  3. pathologically diagnosed late-stage gastric or gastro-esophageal junction
             adenocarcinoma, with measurable lesions outside of primary sites (≥10mm on CT scan, in
             accordance with RECIST 1.1 criteria);

          -  4. refractory to first-line treatment;

          -  5. having received no previous apatinib treatment, nor treatments with other VEGFR
             inhibitors;

          -  6. no anormalies with blood routine tests;

          -  7. no significant dysfunction with heart, lungs, liver and kidneys; no jaundice and GI
             obstruction; not complicated with acute infection.

        Exclusion Criteria:

          -  1. KPS&lt;60, or anticipated survival period＜3 months;

          -  2. cardiovascular and cerebrovascular events within 6 months; uncontrolled
             hypertension (SP&gt;140mmHg，DP&gt;90 mmHg); grade I or above coronary heart disease; grade I
             or above arrhythmia (including QT interval prolongation, male &gt; 450 ms, female &gt; 470
             ms); grade I or above cardiac insufficiency; positive with urinary protein.

          -  3. with definite bleeding tendency of gastrointestinal tract, and with active ulcer
             lesions, and positive with occult blood in stool (+ +); with history of black stool
             and hematemesis within 2 months;

          -  4. abnormal coagulation (INR &gt; 1.5, APTT &gt; 1.5 ULN), and with bleeding tendency;

          -  5. factors that affect the absorption of oral-intaked drugs (such as inability to
             swallow, nausea, vomiting, chronic diarrhea and intestinal obstruction, etc.);

          -  6. with nervous and mental diseases; or with severe infection;

          -  7. pregnant or lactating women or those who have fertility requirements during the
             study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Deng, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 5, 2020</study_first_submitted>
  <study_first_submitted_qc>April 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2020</study_first_posted>
  <last_update_submitted>April 5, 2020</last_update_submitted>
  <last_update_submitted_qc>April 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Zhongtao Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>late-stage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>2020.12~</ipd_time_frame>
    <ipd_access_criteria>via reasonable email requests</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

